Suggested remit: To appraise the clinical and cost effectiveness of dupilumab within its marketing authorisation for treating moderate to severe chronic obstructive pulmonary disease (COPD).
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6235

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
15 May 2024 - 13 June 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6235
15 May 2024 In progress. Scoping commenced.
23 February 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late August 2024 when we will write to you about how you can get involved.
18 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual